vv 001 Citation: Sai YRKM (2021) Vildagliptin-Metformin: Is it a causative of cardiac muscle failure in Type 2 Diabetic patients? Int J Clin Endocrinol Metab 7(1): 001-002. DOI: https://dx.doi.org/10.17352/ijcem.000053 https://dx.doi.org/10.17352/ijcemDOI:2640-7582ISSN: C L I N I C A L G R O U P Introduction Vildagliptin is an oral anti-hyperglycaemic agent, commonly called an anti-diabetic medication that belongs to the family of medications known as Dipeptidyl Peptidase-4 (DPP-4) inhibitors. It is a medicine that is used to treat Type 2 Diabetes Mellitus [1]. It inhibits the inactivation of Glucagon- Like Peptide (GLP-1) and Gastric Inhibitory Polypeptide (GIP) by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas [2], This results in a reduction of hyperglycemia in T2DM [3]. Vildagliptin has been shown to reduce hyperglycaemia in type 2 diabetes mellitus. It does this by stimulating the pancreas to produce more insulin and by inhibiting the production of hormones that contribute to an increase in blood sugar levels. This lowers the amount of sugar in the blood both before and after a meal [4]. The combination of metformin and Vildagliptin is said to be an approved drug as an oral treatment for type -2 diabetes [5]. Adverse effects According to clinical trials, the use of DPP-4 inhibitors such as Vildagliptin has been associated with adverse effects such as nausea, hypoglycemia, tremors, headache, and dizziness [6]. However, hepatotoxicity has been reported to be rare [6]. There have been reports of pancreatitis associated with the use of DPP-4 inhibitors, and some studies have noted the presence of precancerous pancreatic changes in rats and organ Perspective Study Vildagliptin-Metformin: Is it a causative of cardiac muscle failure in Type 2 Diabetic patients?
